News
Puma Biotechnology Reports Third Quarter 2020 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2020. Unless otherwise stated, all comparisons are for
Navidea Biopharmaceuticals to Host Third Quarter 2020 Earnings Conference Call and Corporate Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement
Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the closing of its previously announced offering of
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results and provided a business update for the third quarter ended September 30, 2020.
“The strong U.S. commercial launch
Transgene Reports Business Update and End Q3 2020 Financial Position
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter
Medigene AG: Präsentation und Poster zu klinischer Forschung von Medigene auf der ASH Konferenz
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (05.11.2020) - 5. November 2020. Die Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit
Medigene AG: Oral and poster presentations on Medigene's clinical research at ASH conference
Business news for the stock market
Planegg/Martinsried (05.11.2020) - 5 November 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing
Clovis Oncology Announces Third Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that on November 4, 2020 it entered into a privately negotiated exchange and purchase agreement (the “Agreement”) with a holder of its currently
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
-
29th Annual Credit Suisse Virtual
Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock
Pfizer Inc. (NYSE: PFE) announced today further details regarding the proposed spin-off of its Upjohn Business and the subsequent combination of Mylan and the Upjohn Business to form Viatris Inc
Transgene Presents Its Individualized Immunotherapy, TG4050, at The Annual Neoantigen Based Therapies Summit
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that its Executive
Updated Clinical Data From Phase 2 SPiReL Study Evaluating IMV’s T Cell Therapy in Combination With Merck’s Keytruda® in Patients With r/r DLBCL to Be Presented at The American Society of Hematology Annual Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announces that
Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights.
“We are pleased with the clinical
THERANEXUS : PRESENTATION OF THE RESULTS OF THE PHASE IB CLINICAL STUDY OF THN201 FOR ALZHEIMER'S DISEASE AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE (CTAD)
The conference will take place remotely from 4 to 7 November 2020.
Lyon, 4 November 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer
Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that data from
Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act
Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
GenSight Biologics Reports Validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005955/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Sensorion Announces Attendance and a Presentation at Upcoming Conferences
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement
Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount
Aurinia Announces Outcome of AUDREY™ Clinical Trial in Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced topline data from the Phase 2/3 AUDREY™ clinical
Quantum Genomics Announces End of Financing Agreement with Negma Group Ltd/Park Partners
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and
Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes
Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced its intention to offer $500 million aggregate